Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
Poirot - welcome back on such an auspicious day.
A day to celebrate Avacta’s stunning achievement, to reflect on how this will change people’s health dramatically for the better, and to simply inhale and exhale freely again and without any lingering element of possible uncertainty about success.
A great day for all!
StarBright - many thanks for this detailed and very helpful explanation. Contributions like this make this board a very useful resource, especially for the less financially literate investors like me!
Tom - my own wait is now 9 years - since 2013, but well worth it! Onward Avacta!
Agreed.
The whole RNS just quietly oozes the kind of absolute confidence that derives from AS and the team knowing very well indeed that all is going totally to plan - or possibly even better than that.
They have seen the data.
This is getting very exciting……but trying hard to remain balanced, cool, calm and collected!
Tom - agree.
I believe all money spent on these trials is money very wisely spent.
The likelihood is high that the trial results will be excellent when published soon. If so, then it will not matter one iota if the cash burn has been higher than most people expect, because IF (and it’s a big IF) the company has to raise funding at some point ( whenever) then it will be on the back of superb trial results which will have Big Pharma (and II’s) falling over themselves to get involved. IF a cash raise occurs, then it would not be a distressed raise, but a celebratory one targeting a massive prize.
But I anticipate that a 3996 deal will make any such raise totally unnecessary anyway…..
Excellent and very helpful summary, J-T.
Thanks for sharing your hard work.
Robin - Goodbye….
But is that actually a helpful system?
Timster - fair point.
But it is a shabbily constructed algorithm that is plainly not fit for purpose, given that it fails with such dramatic frequency.
You might imagine it to be within the wit of man to design one that actually works well.
The failure to address this is itself a cause for some concern.
Kevin - agreed, but if, say, that early data tended to suggest (even if it suggested strongly) that the outlook could be excellent, it would surely be wrong to issue an RNS until the ongoing collection of data provided enough evidence to confirm those hopeful early assessments.
Better to make a fully reliable assessment/announcement once the fuller data is in. Could be considered reckless/misleading to do otherwise, even if they feel the signs are generally promising.
My guess is that TomtheBomb’s post is about right on timing etc.
Well, Novartis can’t afford us, then!
Bein - many thanks - very helpful response.
Bein - thanks for sharing this.
Have I understood it right that this is currently pre-clinical only?
If so, we’d have a significant time advantage of several months….
Energyshares - yes, please. me too.
Where do we sign?
This share is potentially worth SO much more than a crappy £5 a shot.
I will be very pee’d off if I don’t get £20 as the absolute bare minimum, on the assumption that AVA6k does the business - and thereby , in effect, validates a whole line of massively valuable treatments.
I’m hoping for at least £40 and , with luck, a shed load more. Fanciful? Maybe. But maybe not…..
I know that this will sound ridiculous to some folk, but I believe the chance could ultimately be there.
The nightmare scenario is a cheap buy out, with Big Pharma laughing themselves stupid all the way to every bank they can find.
This is a once in a lifetime, potentially life changing opportunity for LTH’s (and for cancer patients, of course) and I will not be selling any ‘birthright’ for a mess of pottage……
OK, I admit, it must be time for a second (?) large glass of wine and another soothing pill or two… or three..
Retireby - agree, this is the best analysis of the poster among several good efforts.
To make it comprehensible to a scientific half wit like me is quite an achievement.
Worth a read.
Sorry - aimed at Toutank….
Cobblers!
Thanks, Simon Phoenix.
Encouraging news.
Is this a suitable item for an RNS? Certainly, at least, very positive news, anyway……
GMCC- thanks for posting.
RAH is nothing to do with MM as far as I can tell - and he is often highly critical of AVCT management, especially the management’s failure in his view to do anything to support the SP in particular and private investors in general since the DE RNS…..
His views seem well informed and useful.